表紙
市場調查報告書
商品編碼
236787

肉毒桿菌的全球市場

Botulinum Toxin

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 353 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球肉毒桿菌市場相關調查,彙整市場概要與成長趨勢,產品概要,及加入此市場的主要企業的簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 肉毒桿菌:美容和治療的用途擴大推動成長
    • 治療用肉毒桿菌用途
    • 已開發地區主導市場
    • 發展中國家推動未來的成長
    • 醫療費高等促進治療用肉毒桿菌的需求
    • 美容的肉毒桿菌:有前途的用途市場
    • 帶動美容用肉毒桿菌市場的因素
    • 肌肉骨骼適應數的增加
    • 製藥公司關注有利可圖的BT市場
  • 競爭環境
    • 肉毒桿菌毒素市場競爭激烈
    • Allergan領導全球BTX市場
    • 肉毒桿菌產品
    • 肉毒桿菌:領導品牌
    • 生物相似藥
    • 已經過核准產品缺乏差異化
    • 主要的神經毒素比較
    • 主要的肉毒桿菌產品的檢討 其他
  • 市場趨勢與課題
    • 非侵入性美容治療的需求增加
    • 臉部注射劑市場上偏好的解決方案
    • 肉毒桿菌的人氣
    • 壽命的延長和可支配所得的增加 其他
  • 產品概要
    • 能治療的毒素
    • 結構·作用機制
    • 弱點
    • 分類
    • 手術
    • 美容的應用
    • 治療的應用
    • 副作用
  • 產品引進/認證
  • 近幾年的產業活動
  • 主要企業
    • Allergan Plc
    • Daewoong Pharmaceutical Co., Ltd.
    • HUGEL Pharma
    • Ipsen Group
    • Medy-Tox Inc.
    • Merz Pharma GmbH & Co. KGaA
    • Metabiologics, Inc.
    • Revance Therapeutics, Inc.
    • US WorldMed
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
目錄
Product Code: MCP-1833

Abstract:

Global Botulinum Toxin Market to Reach $7.9 Billion by 2026

Botulinum toxin, a neurotoxin produced by Clostridium Botulinum bacterium, is capable of arresting release of acetylcholine, thus leading to muscle relaxation. Manufactured under controlled laboratory conditions and administered in extremely small therapeutic doses, BTX is administered intravenously only at the affected site. Growth in the global market is driven by growing demand in medical/therapeutic and cosmetic applications. The growing acceptance of facial injectables such as BTX to facial aesthetics among adults and approval for using therapeutic BTX in the treatment of an expanded range of indications is expected to spur market expansion. The constant development and launch of novel products for enhancing aesthetic appeal and the growing demand for minimally invasive treatments in cosmetology as well as therapeutic applications are boosting demand in the market. In the field of neuromuscular therapeutics, the use of botulinum toxin is driven by rising incidences of movement related disorders and growing number of patients with muscle spasms. Further, new clinical indications of botulinum toxin such as in the treatment of nystagmus, stridor, palatal myoclonus, scoliosis, co-spasms following brachial plexus lesions (birth related), and gait freezing (Parkinson), have helped further strengthen growth in this space.

Amid the COVID-19 crisis, the global market for Botulinum Toxin estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2026, growing at a CAGR of 8.2% over the analysis period. Type A, one of the segments analyzed in the report, is projected to record 8.2% CAGR and reach US$8.5 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Type B segment is readjusted to a revised 6.9% CAGR for the next 7-year period. Botulinum toxin type A finds use in the treatment of movement disorders, vocal cord dysfunction and obesity, and is also used as a medical aid in gastric cancer. Growth in the botulinum toxin type A will be driven by its increasing use in the treatment of muscle spasms in cerebral palsy as well as neurogenic bladder diseases occurring in children. Type B is used for various muscle related conditions. Botulinum neurotoxin type B was approved by the FDA in 2000 for treatment of for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain linked with cervical dystonia.

The U.S. Market is Estimated at $3.1 Billion in 2021, While China is Forecast to Reach $665 Million by 2026

The Botulinum Toxin market in the U.S. is estimated at US$3.1 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$665 Million by the year 2026 trailing a CAGR of 14.8% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR. The United States represents the largest regional market, driven mainly by the growing approval for newer therapeutic indications. Further the increasing focus on improving physical appearance, rising disposable incomes of people, and the subsequent rise in demand for cosmetic procedures is also fueling growth. Rising demand for non-invasive or minimally invasive aesthetic treatments is also contributing to the growth of Botox market in the US. Europe also offers attractive opportunities for the botox market owing to the presence of a large number of cosmetic product manufacturers. Rapidly improving socio-economic conditions and proliferation of medical tourism, particularly in Asian countries, presents favorable prospects for botulinum toxin in Asia-Pacific region.

Select Competitors (Total 28 Featured) -

  • AbbVie
  • Daewoong Pharmaceutical Co., Ltd.
  • HUGEL Pharma
  • Ipsen Group
  • Medy-Tox Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Metabiologics, Inc.
  • Revance Therapeutics, Inc.
  • US WorldMeds

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • COVID-19 Disruptions Impact Botulinum Toxin Business
    • Virtual Care to the Fore amid COVID-19
    • Aesthetic Clinics to Follow Infection-Prevention Measures to Mitigate Risk of COVID-19 Infection Transmission
    • EXHIBIT 1: % Rise in Migraine Attacks due to COVID-19 Pandemic for March 2020
    • COVID-19 Disruptions Highlight Significance of Botulinum Toxin Therapy for Associated Medical Conditions
    • Researchers Eye on Botulinum Toxin as Potential Therapeutic Option to Alleviate and Manage COVID-19 Infection
    • Botulinum Toxin: An Introduction
    • Outlook
    • Therapeutic BTX Applications Lead
    • Cosmetic BTX Gradually Gains Momentum
    • Factors Propelling the Cosmetic BT Market: In a Nut Shell
    • EXHIBIT 2: Percent of Plastic Surgeons Performing Botulinum Toxin Surgical Procedures in Select Countries: 2019
    • Developed Regions Dominate Botulinum Toxin Market
    • Developing Markets to Drive Future Growth
    • Competitive Landscape
    • Intense Competition Characterizes Botulinum Toxin Market
    • EXHIBIT 3: Market Share of Leading Players in Global Botulinum Toxin Market: 2019
    • Select Approved Botulinum Toxin Products Worldwide
    • Companies Entering the Fray
    • Pharma Companies Eye Lucrative BT Market
    • Biosimilar BTX Variants Challenge Botox's Leadership
    • Lack of Differentiation among Approved BTX Products
    • Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin by Safety and Efficacy
    • Comparison of Botox®, Dysport® and Xeomin® by Indications and Year of Approval
    • BOTOX®
    • Approvals and Indications of Botox in Select Regions
    • Botox Therapeutic Approvals in the US by Indication
    • Ipsen Counts on New Indications for Future Growth of Dysport
    • Xeomin®
    • Merz
    • Other Products
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market
    • EXHIBIT 4: Non-Surgical Cosmetic Procedures Worldwide (2018): Percentage Breakdown of Procedure Volumes
    • Botulinum Toxin: The Preferred Solution in Facial Injectables Market
    • EXHIBIT 5: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2019): Percentage Breakdown of Procedure Volume by Gender
    • Millennials: A Popular Demographic for Botulinum Toxin
    • EXHIBIT 6: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2019): Percentage Breakdown of Procedure Volume by Age Group Age Group % Share
    • Therapeutic Areas and Opportunities
    • Botox Therapeutic Applications Uses and Indications
    • EXHIBIT 7: Global Therapeutic BTX Neurotoxin Market Breakdown by Therapeutic Indication (2019)
    • Botulinum Toxin Remains Gold Standard for Treatment of Focal Spasticity
    • Rise in the Number of Musculoskeletal Indications: Potential for Growth
    • Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?
    • Combination Therapies: A Double Whammy Success
    • Botulinum Toxin: Potential Applications in Treatment of Dental Diseases
    • Potential Applications in Dentistry
    • Short-lived Aesthetic Effects: A Strong Business Case for Revision Treatments
    • Novel Injection Systems for Highly Precise Dosage of Botulinum Toxin
    • Longer Life Expectancy and Rising Disposable Incomes Propel Sales of Cosmetic BTX
    • EXHIBIT 8: Life Expectancy at Birth in Years of People in Select Countries
    • EXHIBIT 9: Life Expectancy at Birth (in Years) of Men and Women by Region
    • Increase in Healthcare Spending Stirs Demand for BTX in Therapeutic Applications
    • Current Health Expenditure (CHE) as Percentage Of Gross Domestic Product (GDP) (%): 2017
    • EXHIBIT 10: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Challenges and Issues
    • Undesirable Side Effects: A Challenge to Reckon With
    • Immunogenicity Undermines Patient Compliance
    • Antigenicity: A Problematic Issue in Drug Development
    • Potential Adverse Side Effects: A Major Barrier to Success
    • Stringent Regulations Delay Market Approvals
    • Higher Product Costs to Challenge Market Growth
    • Consumer Skepticism: The Biggest Challenge to Beat
    • Animal Cruelty:A Part & Parcel of Botox Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Botulinum Toxin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Botulinum Toxin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Type A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Type A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Type A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Type B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Type B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Type B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Aesthetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Aesthetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Aesthetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Specialty & Dermatology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Specialty & Dermatology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Specialty & Dermatology Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Overview
    • Opportunities in Store for Cosmetic BTX
    • EXHIBIT 11: Age-wise Distribution for Botulinum Toxin Procedures Performed in the US for the Year 2019
    • EXHIBIT 12: Gender Distribution for Botulinum Toxin Procedures Performed in the US (2019)
    • Increasing Demand for Cosmetic Treatments Bodes Well for BTX Market
    • Cosmetic Procedures: Facts and Figures
    • EXHIBIT 13: Number of Surgical & Non-Surgical Cosmetic Procedures ('000s) in the US for the Years 2000, 2018 & 2019
    • EXHIBIT 14: Top 5 Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (In '000s) for 2019
    • EXHIBIT 15: Top 4 Non-Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed ('000s) for 2019
    • EXHIBIT 16: Number of Botulinum Toxin Procedures* Performed in the US: 2000, 2016 and 2019
    • Aging Baby Boomers Drive Aesthetic Business
    • EXHIBIT 17: US Population by Age Group (2017): Percentage Breakdown for 0-14, 15-24, 25-59 and 65+ Age Groups
    • EXHIBIT 18: North American Aging Population by Age Group: 1975-2050
    • Expanding Physician Base Extends Impetus to Growth
    • Therapeutic BTX Seeks Growth Opportunities
    • Approved Therapeutic Indications of Botulinum Toxin in the US by Year of Approval
    • Neurogenic OAB: A Lucrative Market Opportunity
    • Competitive Landscape
    • Major BTX Products and Associated Fillers in the Cosmetic Botulinum Toxin Market
    • EXHIBIT 19: Market Share of Leading Brands in the US Boulinum Toxin Market: 2019
    • Dysport Poses Strong Competition to Botox in the Therapeutic Space
    • TABLE 25: USA Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 34: Canada Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 40: Canada Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • Market Overview
    • EXHIBIT 20: Non-Surgical Aesthetic Procedures in Japan (2019): Percentage Breakdown of Number of Procedures by Procedure Type Procedure % Share
    • TABLE 43: Japan Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 46: Japan Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • Market Overview
    • Uptrend in Facial Injectables Market Favors Market Expansion
    • Regulatory Scenario
    • Approved Botulinum Toxin Injections in China
    • Competition
    • Market Share of Leading Players in Chinese Botulinum Toxin Market: 2019
    • TABLE 52: China Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 58: China Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • Market Overview
    • Botox Approvals and Indications in Select European Countries
    • EXHIBIT 21: Non-Surgical Aesthetic Procedures in Select European Countries (2019): Percentage Breakdown of Number of Procedures by Procedure Type
    • Regulations for Botulinum Toxin Usage in the EU
    • TABLE 61: Europe Current & Future Analysis for Botulinum Toxin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Botulinum Toxin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 73: France Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: France Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: France 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 76: France Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: France Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: France 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 79: France Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 82: Germany Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Germany Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Germany 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 85: Germany Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Germany Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Germany 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 88: Germany Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Germany Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Germany 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 91: Italy Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Italy Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Italy 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 94: Italy Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Italy Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Italy 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 97: Italy Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Italy Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Italy 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • Market Overview
    • Snapshots
    • TABLE 100: UK Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: UK Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: UK 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 103: UK Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: UK Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: UK 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 106: UK Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: UK Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: UK 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 109: Spain Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Spain Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Spain 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 112: Spain Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Spain Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Spain 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 115: Spain Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Spain Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Spain 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • RUSSIA
    • Market Overview
    • TABLE 118: Russia Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Russia Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Russia 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 121: Russia Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Russia Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Russia 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 124: Russia Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Russia Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Russia 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 127: Rest of Europe Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of Europe Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of Europe 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 130: Rest of Europe Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Europe Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Europe 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of Europe Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Europe Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of Europe 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 136: Asia-Pacific Current & Future Analysis for Botulinum Toxin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 137: Asia-Pacific Historic Review for Botulinum Toxin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Asia-Pacific 15-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 139: Asia-Pacific Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Asia-Pacific Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Asia-Pacific 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 142: Asia-Pacific Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Asia-Pacific Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Asia-Pacific 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 145: Asia-Pacific Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Asia-Pacific Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Asia-Pacific 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • Market Overview
    • EXHIBIT 22: Non-Surgical Aesthetic Procedures in Australia (2019): Percentage Breakdown of Number of Procedures by Procedure Type
    • TABLE 148: Australia Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Australia Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Australia 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 151: Australia Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Australia Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Australia 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 154: Australia Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Australia Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Australia 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • INDIA
    • Market Overview
    • EXHIBIT 23: Non-Surgical Aesthetic Procedures in India (2019): Percentage Breakdown of Number of Procedures by Procedure Type
    • TABLE 157: India Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: India Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: India 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 160: India Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: India Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: India 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 163: India Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: India Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: India 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • Market Overview
    • Strong Demand for Cosmetic Procedures - Potential for BTX Market
    • EXHIBIT 24: Working Women as % of Total Female Population for 2005, 2010, 2015 & 2018
    • EXHIBIT 25: Foreign Patients Visiting Korea for Plastic Surgery & Dermatology Procedures as a % of Total Visits of Foreign Patients
    • Competition
    • Market Share of Leading Players in Botulinum Toxin Market In South Korea
    • TABLE 166: South Korea Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: South Korea Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: South Korea 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 169: South Korea Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: South Korea Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: South Korea 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 172: South Korea Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: South Korea Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: South Korea 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 175: Rest of Asia-Pacific Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Rest of Asia-Pacific Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Rest of Asia-Pacific 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 178: Rest of Asia-Pacific Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Rest of Asia-Pacific Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Rest of Asia-Pacific 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 181: Rest of Asia-Pacific Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Rest of Asia-Pacific Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Rest of Asia-Pacific 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 184: Latin America Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Latin America Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Latin America 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 187: Latin America Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Latin America Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Latin America 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 190: Latin America Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Latin America Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Latin America 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 193: Rest of World Current & Future Analysis for Botulinum Toxin by Product - Type A and Type B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of World Historic Review for Botulinum Toxin by Product - Type A and Type B Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of World 15-Year Perspective for Botulinum Toxin by Product - Percentage Breakdown of Value Sales for Type A and Type B for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of World Current & Future Analysis for Botulinum Toxin by Application - Therapeutics and Aesthetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of World Historic Review for Botulinum Toxin by Application - Therapeutics and Aesthetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of World 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Value Sales for Therapeutics and Aesthetics for the Years 2012, 2020 & 2027
    • TABLE 199: Rest of World Current & Future Analysis for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of World Historic Review for Botulinum Toxin by End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Rest of World 15-Year Perspective for Botulinum Toxin by End-Use - Percentage Breakdown of Value Sales for Specialty & Dermatology Clinics, Hospitals & Clinics and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 28